PP405 is a mitochondrial pyruvate carrier (MPC) inhibitor, a genuinely different mechanistic category from anything else covered on this site. Rather than targeting the androgen pathway (finasteride, dutasteride) or growth factor and vascular signalling (copper peptides, 2dDR), PP405 works by shifting cell metabolism. Inhibiting MPC pushes cells toward glycolysis, and in mouse and ex vivo human follicle models, that metabolic shift has been associated with reactivating dormant hair follicle stem cells. It's formulated as a once-daily 0.05% topical gel, developed by Pelage Pharmaceuticals, a company spun out of UCLA in 2018.

Pelage's Phase 2a results, reported in mid-2025, found that roughly 31% of treated participants achieved a greater than 20% increase in hair density by week eight, with no systemic exposure detected across a four-week dosing period. These are sponsor-reported topline figures, not yet a full peer-reviewed publication, so they're useful for understanding the scale of interest but shouldn't be read with the same weight as a published, independently reviewed trial. Phase 3 trials were expected to begin in 2026, with Pelage closing a $120 million Series B in October 2025 to fund that stage.

PP405's own chemical structure was, until this reveal, undisclosed. That created an obvious gap for a research-literate hair loss community to try to fill: JXL069 is a publicly known MPC inhibitor from the same broader academic lineage, structurally related to PP405's mechanism and, unlike PP405, available with a published structure and CAS number from research-chemical suppliers. Through 2025, members of hair loss communities including r/Tressless imported JXL069 from China, believing it to be the same compound as PP405, with at least some going as far as sending samples to analytical testing labs to verify what they'd actually received.

Multiple outlets covering the compound reported that Pelage had stated PP405 was distinct from JXL069, JXL-082, and another related compound, PP30, in response to the growing grey-market activity. We haven't located a formal, dated Pelage press release making that denial explicitly, so we'd treat it as well-corroborated secondhand reporting rather than a primary company statement we can point to directly.

Worth knowing before weighing the current identity claim: JXL069 isn't the first compound the community has bet on. JXL082 circulated earlier under the same "is this secretly PP405?" theory, also from the same UCLA medicinal chemistry lineage and sharing the MPC mechanism, and was never confirmed as PP405 either. A separate pair, sold as "3HP" and "PP30," went through the same cycle after that. Each was a reasonable-looking candidate at the time, based on the same kind of structural and mechanistic proximity now being applied to JXL069, and none of them panned out into a confirmed identity. That doesn't mean the current JXL069 match is wrong, the WHO listing is genuinely stronger evidence than anything the earlier candidates had. But it's a useful reminder that "comes from the right lab, targets the right mechanism" has pointed to the wrong molecule before.

International Nonproprietary Names are assigned through the World Health Organization's INN programme to pharmaceutical substances, with structural information published as part of the naming process. JXL069's own structure was first published by the UCLA team behind PP405's underlying research, in a 2021 medicinal chemistry paper describing a series of MPC inhibitors developed to treat hair loss. The structure published for suvomipic appears identical to the structure that paper assigns to JXL069.

That's a meaningfully different thing from Pelage issuing a statement saying "PP405 is JXL069." It's a structural comparison anyone with the chemistry background can check directly against a document the company was required to publish as part of the INN process; it isn't rumour or forum speculation the way the 2025 belief was. But it's worth holding the distinction between "the published structure appears to match" and "the company has confirmed this publicly," since only the first has actually happened as of writing.

Same molecule doesn't mean same product. Pelage has been explicit that PP405's clinical results depend on more than the compound itself: the company has invested specifically in a proprietary delivery formulation designed to get the molecule into the hair follicle stem cell niche. A research-chemical vendor's JXL069, typically supplied as a raw compound or a simple solution, wasn't developed with that same delivery science, tested for skin penetration at that concentration, or manufactured under any pharmaceutical quality standard. Structural identity of the active molecule doesn't establish that a grey-market product delivers it the same way, at a verified purity, or at a concentration that has any relationship to what Pelage tested.

It's also still an investigational compound. Pelage's own Phase 2a data comes from a four-week dosing period; longer-term safety data doesn't yet exist even for the company's own controlled formulation, let alone for unregulated versions of the underlying molecule. PP405/suvomipic is not approved by the MHRA, FDA, or any regulator. Phase 3 trials and the full regulatory review process still have to happen before that changes, so there's currently no confirmed approval or launch date.

Consistent with how we've covered other investigational or unregulated compounds on this site, we're not covering sourcing, dosing, or use of JXL069 here, and we wouldn't recommend it.

Worth being clear that PP405/suvomipic and the actives we formulate with, AHK-Cu, GHK-Cu, 2dDR, and PTD-DBM, occupy genuinely different categories, not competing claims about the same mechanism. PP405 is an investigational pharmaceutical drug candidate, going through the regulatory trial process a medicine requires before it can make treatment claims. Our actives are cosmetic ingredients with their own, separately documented research bases, sold on that basis, not positioned as a substitute for what a fully trialled drug like PP405 might eventually offer if its Phase 3 results hold up. PTD-DBM is worth noting specifically here: it targets CXXC5, a protein in the same Wnt/beta-catenin signalling territory that intersects with PP405's metabolic mechanism in follicle stem cell biology, even though the two compounds work through distinct pathways to get there.

We'll keep covering PP405/suvomipic's progress as genuinely relevant developments occur, because it's one of the more scientifically interesting entrants in hair loss research in years. The research may be interesting. That doesn't make an unregulated version something we'd recommend using.

This is a fast-moving, recently-developing story. We'll update this article as Pelage or independent sources publish anything further; treat the identity match as current best understanding rather than a permanently settled fact.

This article is provided for educational purposes and does not constitute medical advice. PP405/suvomipic is an investigational drug not approved by any regulator and not available outside Pelage Pharmaceuticals' clinical trials. AmpleLab products are cosmetic formulations, unrelated to PP405, and are not intended to diagnose, treat, cure, or prevent any condition.

AmpleLab.